Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1053/j.jvca.2025.08.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-world use of terlipressin in cirrhosis and acute kidney injury: frequent use beyond hepatorenal syndrome.
Clin Gastroenterol Hepatol
September 2025
Unit of Internal Medicine and Hepatology, Department of Medicine, University and Hospital of Padova, Padova, Italy. Electronic address:
Background & Aims: Terlipressin is indicated to treat hepatorenal syndrome (HRS)-acute kidney injury (AKI), but is likely used outside this primary indication in clinical practice. We aimed to investigate real-world practice patterns on the use of terlipressin in AKI in cirrhosis.
Methods: International prospective study including patients hospitalized for decompensated cirrhosis.
Integrated neurobehavioral and organ-specific safety profiling of baicalin: acute/subacute toxicity studies.
Front Pharmacol
August 2025
School of Integrated Traditional Chinese and Western Medicine, Hebei University of Chinese Medicine, Shijiazhuang, Hebei, China.
Ethnopharmacological Relevance: Baicalin, an extract derived from the dried root of Scutellaria baicalensis Georgi (Huang Qin), has demonstrated neuroprotective properties. Nonetheless, the safety profile of baicalin has not yet been fully elucidated.
Aim Of The Study: The objective was to characterize the acute and subacute toxicity profiles of baicalin across various organ systems, thereby establishing safe therapeutic windows for its clinical application in the treatment of chronic neurodegenerative disorders.
Early Diagnosis and Timely Terlipressin in Hepatorenal Syndrome Improves Projected Outcomes and Lowers Cost.
Clinicoecon Outcomes Res
August 2025
Mallinckrodt Pharmaceuticals, Bridgewater, NJ, USA.
Introduction: Terlipressin is the only Food and Drug Administration-approved medication for adults with hepatorenal syndrome-acute kidney injury (HRS-AKI) with rapid reduction in kidney function. Treatment with terlipressin, particularly in patients with lower serum creatinine (SCr) at diagnosis, improves outcomes. Despite evidence suggesting that treating HRS-AKI at lower SCr thresholds may improve clinical outcomes, the impact on healthcare resource utilization (HCRU) and medical costs of an earlier intervention strategy remains unquantified.
View Article and Find Full Text PDFUse of Terlipressin in Liver Transplant Candidates.
Gastroenterol Hepatol (N Y)
August 2025
Division of Gastroenterology and Hepatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
The use of terlipressin in the treatment of hepatorenal syndrome type 1 (HRS-1) in patients with advanced cirrhosis wait-listed for liver transplant (LT) has been controversial. Successful treatment lowers patients' Model for End-Stage Liver Disease (MELD) score and hence their LT priority. Terlipressin's potential ischemic side effects and risks for respiratory failure in susceptible patients lend support to directly proceed to LT.
View Article and Find Full Text PDFAcute Hepatorenal Failure in the Setting of Ruptured Sinus of Valsalva: Concerns and Considerations.
J Cardiothorac Vasc Anesth
August 2025
Department of Anesthesiology, The Ohio State University Wexner Medical Center, Columbus, OH.